Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroblastoma 9 Precancerous Conditions 3 Adenomatous Polyposis Coli 3 Sarcoma, Ewing 2 Prostatic Neoplasms 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive 2 Medulloblastoma 2 Glioma 2 Colorectal Neoplasms 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Typical Teratoid Rhabdoid Tumor 1 Skin Neoplasms 1 Rhabdoid Tumor 1 Osteosarcoma Recurrent 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Keratosis, Actinic 1 Esophageal Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Colonic Polyps 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Adenomatous Polyps 1

Interventions

pembrolizumab 160 Gemcitabine 147 Paclitaxel 136 Carboplatin 123 Bevacizumab 118 Surveys and Questionnaires 102 Docetaxel 101 Cisplatin 101 Cyclophosphamide 100 Blood Specimen Collection 97 Exercise 93 Nivolumab 87 Capecitabine 81 Fluorouracil 80 Dexamethasone 74 Radiotherapy 71 Irinotecan 68 Pemetrexed 62 Oxaliplatin 62 Standard of Care 60 Leucovorin 58 Drug Therapy 56 Cetuximab 51 Erlotinib Hydrochloride 48 Sorafenib 47 atezolizumab 46 Doxorubicin 44 Interviews as Topic 43 Ipilimumab 40 Therapeutics 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡